Business & Finance
Gollaher Named to Cidara Therapeutics Board of Directors
14 September 2018 - - US-based biotechnology company Cidara Therapeutics, Inc. (NASDAQ: CDTX) has appointed indus David Gollaher, Ph.D., to the company's board of directors, the company said.

Gollaher served as vice president of worldwide government affairs and policy for Gilead Sciences from early 2014 to mid-2018, a period during which the company launched a breakthrough cure for the hepatitis C virus and tripled revenues from USD 10bn to USD 30bn.

In addition to leading the introduction of three novel drugs for HCV, building on Gilead's strength in virology, he was involved in the launch of a new generation of medicines for HIV/AIDS.

Prior to joining Gilead, Gollaher served for 20 years as co-founder and chief executive officer of the California Healthcare Institute.

During this time, he built CHI into a premier state-based life sciences policy research and advocacy association, representing nearly 370 biopharma, medical device and diagnostics companies, along with leading academic institutions, venture capital and professional services firms.

Earlier in his career, Gollaher was vice president at Scripps Clinic and Research Foundation, responsible for managed care, strategy and corporate affairs.

Additionally, in June of 2018, Dr. Gollaher was appointed a Senior Fellow at the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California.

He also currently serves on Gilead's Health Policy advisory board and the board of Overseers for The Scripps Research Institute. He earned a Bachelor of Arts degree from University of California Santa Barbara and both masters and doctorate degrees from Harvard University.

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients' lives.

The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, formerly known as CD101 IV, through clinical trials.

Rezafungin has improved pharmacokinetics compared to existing echinocandins and the potential for expanded utility across patient settings.

It is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections.

The company's Phase 2 STRIVE clinical trial of rezafungin met its primary safety and efficacy objectives, and provides support for Cidara to initiate Phase 3 pivotal trials in the treatment of candidemia and invasive candidiasis and the prophylaxis of invasive fungal infections.

Cidara also is leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of multi-drug resistant Gram-negative bacterial infections.

Cloudbreak is the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient's immune cells to attack and eliminate bacterial, fungal or viral pathogens.

Cidara is headquartered in San Diego, California.